BioReliance® Launches Ground Breaking 3D Skin Assay
ROCKVILLE, Md., Sept. 5, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that its recent acquisition, BioReliance, the biopharma and early development services business under SAFC, will introduce a new assay to detect DNA damage from products with dermal routes of exposure. The Reconstructed Skin Micronucleus (RSMN) Assay represents the first commercial offering of a Genetic Toxicology assay using three-dimensional tissue models.
The RSMN Assay uses the EpiDerm™ three-dimensional skin model, developed by global tissue engineering industry leader, MatTek. Three-dimensional models are increasingly being used in predictive toxicology, as they require no animal models, more closely resemble human organs, and have proven to be more predictive than other in vitro models.
BioReliance has performed extensive qualification studies of this assay using chemicals with defined genotoxicity/carcinogenicity and has developed a robust Good Laboratory Practices (GLP) protocol. The results of these studies have been presented in numerous meetings, including sessions at the Society of Toxicology (SOT), Environmental Mutagen Society (EMS), and International Life Science Institute (ILSI)/In Vitro Genetic Toxicity (IVGT) meetings; as well as posters, most recently presented at the Congress of the European Society of Toxicology Annual Meeting, Eurotox 2012 and the United Kingdom EMS meeting.
"We are very proud to introduce this novel genotoxicity assay that represents a paradigm shift from traditional genotoxicity testing, and a step forward in further contributing to the 'three R's' of reduce/refine/replacement of animal tests," said Executive Director for Early Development Services, Daniel Aparicio . "BioReliance places significant emphasis on the development of new assays and innovative technologies. The RSMN Assay is the latest endeavor in our continuing demonstration of leadership in Genetic Toxicology."
The foregoing release contains forward-looking statements that can be identified by terminology such as "will introduce," "increasingly being used," "continuing demonstration of leadership" or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the Reconstructed Skin Micronucleus Assay will meet the demands of the marketplace. Nor can there be any guarantee that this assay will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
BioReliance was acquired by Sigma-Aldrich Corporation, in January 2012 to supply customers access to a powerful, single-point provider whose products and services span the drug discovery, development and commercialization pipeline. As part of the SAFC business unit, BioReliance is a leading provider of cost-effective contract services, offering more than 1,000 tests or services related to biologics safety testing, specialized toxicology and animal health services. BioReliance has over 700 employees and has laboratory operations in Rockville, MD and Scotland. For more information, visit www.bioreliance.com.
About SAFC: SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.safcglobal.com.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology SAFC manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,100 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.
©2012 Sigma-Aldrich Co. LLC. All rights reserved. BioReliance and SAFC are trademarks of Sigma-Aldrich Co. LLC or its Affiliates, registered in the US and other countries.
EpiDerm™ is a trademark of MatTek Corp.
SOURCE Sigma-Aldrich Corporation
More by this Source
Correction Notice Of Press Release On Quarterly Dividend Announcement
May 08, 2013, 09:40 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.